Blog Post
P-Values
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Featured
P-Values
showing 1-10 of 1284
Building Public Trust Through Evidence-Based Media Engagement
Advancing Access to LEN Learning in Practice: Reports from our Partners — Uganda The successful introduction of a new HIV prevention technologies depends on health system readiness, public understanding and trust. Journalists play a critical...
Prevention Option:
Community involvement in materials design increases awareness of and demand for LEN and PrEP choice among priority populations
Advancing Access to LEN Learning in Practice: Reports from our Partners – Malawi As part of a project to provide technical support to the Ministry of Health around LEN introduction, Pakachere led the development of awareness and...
Prevention Option:
Supporting the Ministry of Health to implement LEN in-country
Advancing Access to LEN Learning in Practice: Reports from our Partners — Kenya In advance of LEN rollout in Kenya, Lvcthealth worked closely with NASCOP and county HIV teams, to support planning and preparations at the country and facility...
Prevention Option:
Global Health Watch: What a New US Congress Could Mean for Science + Global Health, America First Global Health Strategy, Measles Resurgence
The wave of newly elected US lawmakers with backgrounds in science and global health offers new opportunities for advocacy and oversight; a ProPublica exposé reveals nearly $40 million in federal health security awards to a company linked to the US President’s family amid the rollout of the “America First Global Health Strategy”; and the potential loss of US measles elimination status underscores the consequences of eroding trust in science and the spread of disinformation.
Clinical Trial Design Academy: Shaping the Future of HIV R&D
AVAC’s Clinical Trial Design Academy (CTDA), established in 2019, is the only program of its kind equipping advocates with the scientific knowledge and skillset to influence research and development (R&D) from priority setting and upstream vaccine, bNAb, ARV and MPT research through ongoing efficacy trials, results dissemination, implementation science and, ultimately, access. Today, the Academy’s 27 members are premier advocates who are directly influencing HIV research. Last month, the Academy gathered in Cape Town, South Africa. Read on to learn more about the Academy and the advocates who are bridging the gap between science and communities.
From Capacity to Advocacy: How the CTDA Is Shaping My Role in HIV Research
When Idah Mulalah joined AVAC’s Clinical Trial Design Academy (CTDA) in 2024, she thought it would be like joining any other group where we meet, discuss, learn and move on. In this guest blog post, she reflects on how much the experience has transformed her understanding of clinical trials, and how she sees her role as an HIV prevention research advocate.
Topic:
Global Health Watch: A New Congress and a New Cadre of Scientific Leadership, US FDA Approves Generic LEN, Future of Global Fund
The US midterm elections this week brought significant changes to Congress, creating both new opportunities and uncertainties for the future of science, global health and HIV. This is a moment that is both “celebratory and scary,” with much to unpack about what a new Congress will mean for US policies and investments. With potentially more than 100 new members taking office in January, the need for education, engagement and advocacy will be critical to securing supportive policies and sustainable funding for US-led global health programs and research. This issue examines what the election results mean for science and global health, the US FDA regulatory approval of generic lenacapavir for HIV PrEP (LEN), and Mark Dybul’s vision for the Global Fund amid shrinking resources and shifting priorities.
Global Health Watch: State Dept. diverts millions for contraception, who’s leading US global health, new Global Fund ED, UNAIDS’ future
For nearly two years, the US Administration has ignored Congress and denied women and couples of life-saving sexual and reproductive health commodities. So this week’s breaking news that the US Department of State is shifting millions of dollars appropriated by Congress for contraception to “stem some of the bleeding they’ve caused by starting a reckless war and creating a global energy crisis” is perhaps not surprising. But it is appalling, nonetheless. With the US midterm elections happening next week, all members of Congress, irrespective of party or ideology, should be speaking up and taking back their power of the purse.
AVAC Applauds Appointment of Mark Dybul as Executive Director of the Global Fund
AVAC applauds the appointment of Mark Dybul as Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. His return to the Global Fund comes at a pivotal moment for global health, as funding pressures, political threats and persistent inequities threaten hard-won progress against the three diseases.
Global Health Watch: Hepatitis B vaccine trial halted, HIV advocates demand action, LEN for PrEP access, Global Fund’s malaria accelerator
International pressure halted a controversial hepatitis B vaccine trial in Guinea-Bissau; HIV advocates rallied to protect US research funding as the midterm elections approach; and AVAC and Access Bridge call for accelerated access to LEN for PrEP. Meanwhile, the Global Fund prepares to select a new leader at its board meeting next week and vote on a proposed $2-3 billion malaria funding mechanism that could reshape the role of private philanthropy and country ownership in global health financing.
showing 1-10 of 1284
Explore More News and Communications
P-Values Blog
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
Advocates Network
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
Weekly News Digest
A comprehensive round-up of HIV prevention media coverage and scientific publications.
PxPulse
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
Press Releases
A collection of official statements from AVAC.
AVAC in the News
Media clippings featuring AVAC, its staff and close partners in the news media.